(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/211859 A1

(51) International Patent Classification:
A61K 31/395 (2006.01) *A61K 31/4184* (2006.01)
A61K 31/44 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:
PCT/US2023/019659

(22) International Filing Date:
24 April 2023 (24.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/334,942	26 April 2022 (26.04.2022)	US
63/349,250	06 June 2022 (06.06.2022)	US
63/349,408	06 June 2022 (06.06.2022)	US

(71) Applicant: **PRAXIS PRECISION MEDICINES, INC.** [US/US]; 99 High Street, 30th Floor, Boston, MA 02110 (US).

(72) Inventors; and

(71) Applicants: **KAHLIG, Kristopher, Mathieu** [US/US]; c/o Praxis Precision Medicines, 99 High Street, 30th Floor, Boston, MA 02110 (US). **NOVAK, John** [US/US]; c/o Praxis Precision Medicines, 99 High Street, 30th Floor, Boston, MA 02110 (US). **WITTMANN, Marion** [DE/US]; c/o Praxis Precision Medicines, 99 High Street, 30th Floor, Boston, MA 02110 (US).

(74) Agent: **MARGOLIN, Yelena** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/211859 A1

(54) Title: TREATMENT OF NEUROLOGICAL DISORDERS



(57) Abstract: The present disclosure is generally directed to methods of treating a disease, disorder, or condition, e.g., a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with de novo gain-of-function or loss-of-function mutations in major central nervous system sodium channel genes, such as for example, SCN1A, SCN2A, and SCN8A, using Compound 1 of the following formula: or a pharmaceutically acceptable salt thereof.